Celiac Disease Pipeline Insight

DelveInsight’s, “Celiac Disease – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Celiac Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Celiac Disease Understanding

Celiac Disease: Overview

Celiac disease is a digestive disorder caused by an abnormal immune reaction to gluten. Celiac disease is also known as: sprue, nontropical sprue, gluten-sensitive enteropathy. In celiac disease, the immune response to gluten creates toxins that destroy the villi. When the villi become damaged, the body is unable to absorb nutrients from food. This can lead to malnutrition and other serious health complications, including permanent intestinal damage. People with celiac disease often have high levels of antiendomysium (EMA) and anti-tissue transglutaminase (tTGA) antibodies. These can be detected with blood tests. Tests are most reliable when they’re performed while gluten is still in the diet. Some common symptoms of celiac disease include: Gastrointestinal symptoms, such as abdominal cramps, diarrhea, gas, nausea and vomiting, and bloating, Foul-smelling stools with excess fat in them, Bone and joint pain, Depression, irritability, and panic attacks, Weakness and fatigue, Easy bruising and nose bleeds, Fluid retention, and Infertility. Doctors treat celiac disease by prescribing a gluten-free diet. Symptoms significantly improve for most people with celiac disease who follow a gluten-free diet. A dietitian can teach you how to avoid gluten while following a healthy and nutritious diet.


"Celiac Disease - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Celiac Disease pipeline landscape is provided which includes the disease overview and Celiac Disease treatment guidelines. The assessment part of the report embraces, in depth Celiac Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Celiac Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Celiac Disease R&D. The therapies under development are focused on novel approaches to treat/improve Celiac Disease.

Celiac Disease Emerging Drugs Chapters

This segment of the Celiac Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Celiac Disease Emerging Drugs


Larazotide: 9 Meters Biopharma, Inc.

Larazotide represents the only Phase III therapeutic in development for celiac disease, with data readouts expected in 2022. Larazotide prevents the gluten breakdown product gliadin from entering into the systemic circulation and propagating an inflammatory response. 9 Meters aims to introduce larazotide as an adjunctive therapy in celiac disease to restore physiology and thus minimize symptoms in tandem with a gluten-free diet.


Latiglutenase: Immunogenics

Latiglutenase (IMGX003) is an orally administered mixture of two gluten-specific recombinant proteases that degrades gluten proteins into small physiologically irrelevant fragments, and is to be administered as an adjunct to a gluten-free diet (GFD). IMGX001 is effective at breaking glutamine-leucine bonds and the other protease (IMGX002) targets most proline bonds. In Phase IIa and IIb clinical trials Latiglutenase has been shown to mitigate gluten-induced intestinal mucosal injury as well reduce the severity and frequency of symptoms in celiac disease patients. ImmunogenX is beginning a Phase II gluten-challenge study to investigate both mucosal and symptomatic protection in a general population of CD patients. This study will be followed shortly by a Phase II/III real-world trial that will focus on symptom improvement in seropositive patients as a prelude to a Phase III trial.

Further product details are provided in the report……..

Celiac Disease: Therapeutic Assessment

This segment of the report provides insights about the different Celiac Disease drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Celiac Disease

There are approx. 25+ key companies which are developing the therapies for Celiac Disease. The companies which have their Celiac Disease drug candidates in the most advanced stage, i.e. Phase III include, 9 Meters Biopharma, Inc.

Phases

DelveInsight’s report covers around 25+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Celiac Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Celiac Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Celiac Disease therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Celiac Disease drugs.

Celiac Disease Report Insights

  • Celiac Disease Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Celiac Disease Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Celiac Disease drugs?
  • How many Celiac Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Celiac Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Celiac Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Celiac Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Celiac Disease: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Larazotide: 9 Meters Biopharma, Inc.

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Latiglutenase: Immunogenics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early stage products (Phase I)

  • Comparative Analysis

KAN-101: Kanyos Bio

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Celiac Disease Key Companies

Celiac Disease Key Products

Celiac Disease- Unmet Needs

Celiac Disease- Market Drivers and Barriers

Celiac Disease- Future Perspectives and Conclusion

Celiac Disease Analyst Views

Celiac Disease Key Companies

Appendix

List of Table

Table 1: Total Products for Celiac Disease

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Celiac Disease

Figure 2: Late Stage Products                              

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• 9 Meters Biopharma

• ImmunogenX

• Provention Bio, Inc.

• Takeda

• Amgen

• ImmusanT

• Janssen Research & Development, LLC

• Kanyos Bio

• Calypso Biotech

• Protagonist Therapeutics

• ActoBio Therapeutics

• Bioniz Therapeutics

• Dr Falk Pharma

• Allero Therapeutics

• PvP Biologics

• Topas Therapeutics

• GlaxoSmithKline

• Amyra Biotech AG

• Parvus Therapeutics

• Precigen Inc

• Ahead Therapeutics

  • Tags:
  • Celiac Disease Pipeline
  • Celiac Disease clinical trials
  • Celiac Disease companies
  • Celiac Disease drugs
  • Celiac Disease therapies
  • Celiac Disease treatment algorithm
  • Celiac Disease pipeline drugs
  • Celiac Disease pipeline companies

Forward to Friend

Need A Quote